Market Trends of Traveler's Diarrhea Treatment Industry
Antibiotics Segment is Expected to Hold Significant Share Over the Forecast Period
A course of antibiotics helps treat diarrhea caused by bacteria or parasites. Most of the time, over-the-counter drugs like antibiotics can help reduce the discomfort associated with traveler's diarrhea. For the treatment of severe traveler's diarrhea, azithromycin is preferred. Traveler's diarrhea that is severe and not dysentery-related may be treated with fluoroquinolones. Traveler's severe diarrhea and non-dysentery can be treated with rifaximin. Traveler's diarrhea can be treated with single-dose antibiotic regimens.
The increasing prevalence of traveler's diarrhea is expected to boost the segment's growth. For instance, according to the article published in Travel Medicine and Infectious Diseases in February 2022, travel-related diarrhea (TD) is the most common sickness among travelers from high-income countries to middle- or low-income countries. Every year, almost 80 million people who travel internationally get diarrhea. Because of this, TD has always been and still is a major issue on a global scale. Thus, the significant burden of traveler's diarrhea is expected to boost the demand for antibiotic drugs, thereby boosting the segment's growth.
According to the study published in Tropical Diseases and Infectious Diseases in November 2022, almost all medical experts participating in pre-travel counseling frequently advise clients to purchase antibiotics as preventative medicine. Rifaximin was accurately identified by about 60% of the participating physicians as a treatment option for severe, non-dysenteric TD and as a preventative option for patients at high risk for consequences. Thus, the significance of antibiotics in traveler's diarrhea treatment is expected to boost the demand for antibiotics, thereby boosting the market segment's growth.
North America Holds Significant Share in the Market and is Expected to Grow During the Forecast Period
The North American region holds the largest share of the market due to the increasing burden of traveler's diarrhea and the strong presence of manufacturers in this region. The rising awareness, along with the easy availability of over-the-counter medications, is likely to favor the growth of the market in North America.
In the United States, the growing number of international travelers visiting the country for leisure trips and the rising business travel within the country are driving the traveler's diarrhea treatment market. For instance, according to the US Department of Commerce report in June 2022, international visitors within the country increased from 19.2 million in 2020 to 22.1 million in 2021. Thus, increasing tourism in the United States may lead to more cases of traveler's diarrhea, which would ultimately boost the market's growth over the forecast period.
The strategic activities by the market players, such as product launches, mergers and acquisitions, and partnerships, are expected to propel the market's growth in the region over the forecast period. For instance, in December 2022, Immuron Limited announced that it had received approval from the US FDA to proceed with the clinical evaluation of Travelan. The Investigational New Drug (IND) application to evaluate the efficacy of a single dose of Travelan to prevent infectious diarrhea caused by Enterotoxigenic E.coli (ETEC) is now active.
Thus, all such factors are expected to boost the market in the region over the forecast period.
